{"id":90622,"date":"2026-05-18T14:26:52","date_gmt":"2026-05-18T08:56:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=90622"},"modified":"2026-05-18T14:26:54","modified_gmt":"2026-05-18T08:56:54","slug":"gland-pharma-share-price-52-week-high-q4-fy26-results-may-18-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-52-week-high-q4-fy26-results-may-18-2026\/","title":{"rendered":"Gland Pharma Share Price Jumps 16.22% to Rs 2,170, Hits 52-Week High on Q4 FY26 Results: PAT Nearly Doubles, CDMO Grows 65%"},"content":{"rendered":"

The Gland Pharma share price<\/strong> surged 16.22 percent to Rs 2,170 on 18 May 2026, hitting a fresh 52-week high, as the company reported exceptional Q4 FY26 results. Net profit for the quarter ended 31 March 2026 jumped 96.56 percent year-on-year to Rs 366.67 crore, revenue grew 22.30 percent to Rs 1,742.79 crore and EBITDA surged 48 percent to Rs 513 crore with margins expanding to 29.4 percent. The company also declared a final dividend of Rs 20 per share, providing an income catalyst alongside the strong growth numbers.<\/p>

The Gland Pharma share price hitting a 52-week high of Rs 2,170 on a day when the broader market was under pressure from crude above $111 and the rupee at a record low of 96.17 demonstrates the exceptional relative strength of the pharma sector in the current crisis. This is a rare case of a stock outperforming massively on a macro-challenged market day, driven purely by business fundamentals.<\/p>

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n